PMID- 21461967
OWN - NLM
STAT- MEDLINE
DCOM- 20120918
LR  - 20211020
IS  - 1559-131X (Electronic)
IS  - 1357-0560 (Linking)
VI  - 29
IP  - 2
DP  - 2012 Jun
TI  - Molecular cytogenetic study of derivative chromosome 9 deletion in chronic 
      myeloid leukemia patients.
PG  - 1151-60
LID - 10.1007/s12032-011-9918-8 [doi]
AB  - The aims of this study are to investigate the frequency of derivative chromosome 
      9 (der (9)) deletion in Tunisian patients with chronic myeloid leukemia (CML) and 
      to assess the correlation between this deletion and the cytogenetic response for 
      patients treated with hydroxyurea (HU) or imatinib (IM). Karyotype analysis of 
      336 patients with CML was performed with R-banding technique. Fluorescence in 
      situ hybridization (FISH) was carried using home-brew probes 17L7 and 248J22 for 
      detecting, respectively, adjacent 5'ABL and 3'BCR deletions on der(9). 
      Cytogenetic study demonstrated typical t(9;22)(q34;q11) translocation in 89.6% 
      and variant translocation in 10.4% of patients. Interphase FISH studies showed 
      deletion of der(9) in 59 (17.6%) of the 336 patients, 23 (39%) of them had 
      variant rearrangements. There are 19 patients with solely 5'ABL deletion and 40 
      with concomitant 5'ABL and 3'BCR deletions. Cytogenetic response was evaluated 
      during 18 months with HU or IM therapy. Our results demonstrate that (a) 3'BCR 
      deletion is associated with 5'ABL deletion in all patients with der(9) deletions, 
      (b) the 5'ABL and 3'BCR deletions arise simultaneously with t(9;22), (c) 
      deletions on der(9) chromosome were frequently encountered in older patients and 
      in patients presenting variant rearrangements, (d) both 5'ABL and 3'BCR deletions 
      were associated with cytogenetic response failure in patients treated with HU, 
      however, patients treated with IM and carrying der(9) deletions presented better 
      cytogenetic response.
FAU - Bennour, Ayda
AU  - Bennour A
AD  - Department of Cytogenetics, Molecular Genetics and Reproductive Biology, Farhat 
      Hached University Teaching Hospital, Sousse, Tunisia. aydabennour@yahoo.fr
FAU - Ouahchi, Ines
AU  - Ouahchi I
FAU - Ben Youssef, Yosra
AU  - Ben Youssef Y
FAU - Zaier, Monia
AU  - Zaier M
FAU - Laatiri, Mohamed Adnene
AU  - Laatiri MA
FAU - Harrabi, Imed
AU  - Harrabi I
FAU - Meddeb, Balkis
AU  - Meddeb B
FAU - Elloumi, Moez
AU  - Elloumi M
FAU - Khelif, Abderrahim
AU  - Khelif A
FAU - Saad, Ali
AU  - Saad A
FAU - Sennana, Halima
AU  - Sennana H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110403
PL  - United States
TA  - Med Oncol
JT  - Medical oncology (Northwood, London, England)
JID - 9435512
RN  - 0 (Benzamides)
RN  - 0 (DNA Probes)
RN  - 0 (Piperazines)
RN  - 0 (Pyrimidines)
RN  - 8A1O1M485B (Imatinib Mesylate)
RN  - EC 2.7.10.2 (Proto-Oncogene Proteins c-abl)
RN  - EC 2.7.11.1 (BCR protein, human)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-bcr)
RN  - X6Q56QN5QC (Hydroxyurea)
SB  - IM
MH  - Adult
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Benzamides
MH  - *Chromosome Deletion
MH  - Chromosomes, Human, Pair 22/*genetics
MH  - Chromosomes, Human, Pair 9/*genetics
MH  - DNA Probes
MH  - Female
MH  - Humans
MH  - Hydroxyurea/administration & dosage
MH  - Imatinib Mesylate
MH  - In Situ Hybridization, Fluorescence
MH  - Karyotyping
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy/*genetics
MH  - Male
MH  - Middle Aged
MH  - Philadelphia Chromosome
MH  - Piperazines/administration & dosage
MH  - Prognosis
MH  - Proto-Oncogene Proteins c-abl/genetics
MH  - Proto-Oncogene Proteins c-bcr/genetics
MH  - Pyrimidines/administration & dosage
MH  - Retrospective Studies
MH  - Translocation, Genetic/genetics
EDAT- 2011/04/05 06:00
MHDA- 2012/09/19 06:00
CRDT- 2011/04/05 06:00
PHST- 2011/03/15 00:00 [received]
PHST- 2011/03/18 00:00 [accepted]
PHST- 2011/04/05 06:00 [entrez]
PHST- 2011/04/05 06:00 [pubmed]
PHST- 2012/09/19 06:00 [medline]
AID - 10.1007/s12032-011-9918-8 [doi]
PST - ppublish
SO  - Med Oncol. 2012 Jun;29(2):1151-60. doi: 10.1007/s12032-011-9918-8. Epub 2011 Apr 
      3.